PRODUCT DESCRIPTION:

Vincristine is a cytotoxic chemotherapy agent belonging to the vinca alkaloid class, derived from the periwinkle plant (Catharanthus roseus).

It works by binding to tubulin and inhibiting microtubule formation, thus preventing cancer cell mitosis. It is a critical component of several combination chemotherapy regimens used in both pediatric and adult cancers.

The pre-filled syringe format ensures superior sterility, safety, and reduced risk of dosage errors—particularly important for high-alert medications like vincristine.

Formulation & Presentation:

• Dosage Form: Sterile Injectable (Sterile Lyophilized Solution for Reconstitution)
• Presentation: Pre-Filled Syringe (customizable as per market demand)
• Available Strengths:
  • 11 MG/ ML (Pre-Filled Syringe)
  • 20 MG/ 2ML (Pre-Filled Syringe)
  • 50 MG/ 5 ML (Pre-Filled Syringe)
• Route of Administration: Intravenous (IV), as per clinical indication and severity. Reconstituted as per protocol Intravenous Injection. To be administered under supervision of a qualified oncologist or day-care oncology units. (As per physician’s discretion or decision) Administered as part of chemotherapy regimens.

Therapeutic Indications:

• Acute Lymphoblastic Leukemia (ALL)
• Hodgkin’s and Non-Hodgkin’s Lymphoma
• Wilms’ Tumor
• Neuroblastoma
• Rhabdomyosarcoma
• Ewing’s Sarcoma
• Multiple Myeloma (in combination regimens)
• Small Cell Lung Cancer (SCLC)

Side Effects:

• COMMON:
  • Peripheral neuropathy (dose-limiting)
  • Constipation
  • Alopecia
  • Jaw pain
  • Mild leukopenia
  • Local injection site irritation
• SERIOUS (RARE):
  • Severe neurotoxicity (motor weakness, cranial nerve involvement)
  • SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion)
  • Paralytic ileus
  • Severe myelosuppression (though less common with vincristine)
  • Accidental intrathecal administration is uniformly fatal
• PRECAUTIONS:
  • Absolutely contraindicated for intrathecal use – special labeling and handling required
  • Use with caution in patients with pre-existing neuropathies or hepatic impairment
  • Monitor for signs of neurotoxicity, including jaw pain, paresthesia, and difficulty walking
  • Adjust dosage based on clinical response and toxicity
  • Pregnant and breastfeeding women should avoid exposure
  • Administer only under direct supervision of an oncology specialist